You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 1 - 10 of 12044 results
  1. Asylon Automated Robotics for Automated Perimeter Security

    SBC: ASYLON INC            Topic: AF20RDCSO1

    During this 48-month period of performance, Asylon, Inc. (“Asylon”) will complete the RDT&E necessary to refine the DroneCore platform to the point of scalable deployment across AFGSC and the DAF. Asylon has broken this development into several different

    SBIR Phase II 2023 Department of DefenseAir Force
  2. X-Hab Reef: Sustainable Carbon-Neutral Materials for 3D-Printable Coastal Infrastructure

    SBC: X-HAB 3D, INC.            Topic: HR0011SB2022401

    We propose to engage in a parallel, two-track approach for Phase II in order to expedite the availability of Reefense artificial reefs to protect DoD’s coastal facilities. Track 1 of this approach will initially use our 3D Concrete Printing (“3DCP”) system and traditional concrete mixtures modified to sequester carbon, to 3D print the novel reef structures designed by the Applied Research La ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  3. Digital Uroflowmetry for Office and Home

    SBC: UROGENIE LLC            Topic: 400

    Abstract Uroflowmetry is the most common urodynamic test performed by urologists to assess the function of the lower urinary tract. This simple non-invasive study measures urinary flow rates and when summarized graphically offers insights into various types of lower urinary tract symptoms. Current systems call upon a patient to void into a commode with a funnel to direct the flow of urine into a v ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. Treatment of Inflammatory Complications of Respiratory Infection

    SBC: Respana Therapeutics, Inc            Topic: NIAID

    Abstract Respana Therapeutics is advancing a proprietary first-in-class therapeutic monoclonal antibody (mAb), RT- 002, for the treatment of debilitating and often lethal inflammatory complications associated with acute respiratory conditions. We have identified a lead candidate, RT-002, and an equally promising alternative. RT-002 targets the surfactant protein A receptor SP-R210, a host-mediated ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Slippery Omniphobic Coating for Hemodialysis Catheter to Resist Fibrin Sheathing and Infection and Improve Patient Outcomes

    SBC: FREEFLOW MEDICAL DEVICES LLC            Topic: 400

    PROJECT SUMMARY Approximately 80% of patients beginning hemodialysis (HD) in the United States use a catheter at treatment initiation, and 18.6% of all HD patients were using a catheter in 2017. However, the HD catheters (HDC) used for longer-term dialysis in patients have a high complication rate because of infections and dysfunction, with a catheter dysfunction rate of 0.5–3.42 episodes/1000 c ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of orally bioavailable inhibitors for the treatment of COVID-19 and other human coronavirus infections

    SBC: VENATORX PHARMACEUTICALS INC            Topic: NIAID

    PROJECT SUMMARY The emergence of SARS-CoV-2 in 2019 has resulted in an ongoing epidemic of acute respiratory illness that has stressed the world’s health care systems and led to rt6 million deaths. The lack of therapeutic options for treating coronavirus infections continues to expose the population to grave risk from emerging variants as well as future zoonotic coronavirus infections. Accelerat ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Hardening Ground Vehicles with FPGAs

    SBC: WEB SENSING, LLC            Topic: HR0011SB2022406

    Under the DARPA Assured MicroPatching (AMP) program, Web Sensing has already developed initial proof-of-concept hardware building blocks and automated processes that support precision CAN-bus monitoring and secure patching of ground vehicle control system binaries. Here we seek to impact maintenance crews by development of a new technology portfolio that incorporates a Vehicle Analysis Toolkit - f ...

    SBIR Phase II 2023 Department of DefenseDefense Advanced Research Projects Agency
  8. Non-surgical treatment option for pelvic organ prolapse

    SBC: REIA LLC            Topic: NICHD

    Project Summary / Abstract Reia is working to address a prevalent gynecological condition, pelvic organ prolapse (POP), which affects more than 50% of women over the age of 50. POP occurs when the pelvic floor connective tissue and muscles weaken, allowing the uterus or vaginal walls to descend. In extreme cases, the uterus descends through the opening of the vagina and hangs outside of the body. ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Trypanocidal Agents that Kill Multiple Stages of the Trypanosoma cruzi Life Cycle

    SBC: FOX CHASE CHEMICAL DIVERSITY CENTER INC.            Topic: NIAID

    Abstract. Chagas disease is a neglected tropical disease and has been designated as a research priority by NIAID and an SBIR Research Topic of Interest. Six million individuals are infected and 8,000 deaths were caused by Chagas in 2015 in mostly Central and South America by advanced forms of the disease such as Chagas hemorrhagic fever. The cost associated with Chagas disease treatment globally i ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. A human monoclonal antibody therapy for treatment of hantavirus cardiopulmonary syndrome

    SBC: CELDARA MEDICAL, LLC            Topic: NIAID

    PROJECT SUMMARY Rodent-borne viral outbreaks are increasing in both frequency and impact. As weather patterns evolve, rodent populations are affected and may multiply in areas where increased contact with humans results in infection. Hantaviruses, including Andes (ANDV) and Sin Nombre (SNV), are transmitted through the excreta of infected rodents and, when aerosolized, infect humans. In the Americ ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government